New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
09:09 EDTAStudy shows major advantages of HER2 IQFISH pharmDx in breast cancer diagnostics
Dako, an Agilent Technologies company, announced positive findings in an independent French multicenter study on the performance of Dako's HER2 IQFISH pharmDx. The Toulouse, France, breast cancer group led by Magali Lacroix-Triki has published a peer-reviewed publication in the Journal of Histopathology that supports the use and performance of Dako's HER2 IQFISH pharmDx for HER2 gene amplification status assessment in breast cancer. Dako introduced the cutting- edge IQFISH hybridization buffer chemistry in 2012. The IQFISH buffer reduces test turnaround time from 17 hours to just 3.5 hours. As an aid in the treatment decision, HER2 IQFISH pharmDx can quantitatively determine HER2 gene amplification in the tumor. The French study found that Instant Quality, or IQ, FISH provides "excellent quality signals without any background staining, thus allowing excellent reading conditions." The study also points out "almost perfect agreement between IQFISH and FISH" and that IQFISH is a "safe, reliable and fast method that is easy to use in routine practice" with few reruns. The statement is significant in that the tissue came from five different laboratories using four different fixation methods. The study concludes that the highly concordant results and assay robustness support IQFISH as a useful alternative to FISH, allowing reliable assessment of HER2 status. It also finds that using this method enables pathologists to report the results to the oncologist within a day, meaning patients can begin cancer treatment sooner than ever.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2014
17:08 EDTABulls see Keysight Technologies rising 30%, Barron's says
Subscribe for More Information
November 20, 2014
16:14 EDTAAgilent announces dividend of 10c per share
Agilent Technologies announced that a quarterly dividend of 10c per share of common stock will be paid on Jan. 28, 2015, to all shareholders of record as of the close of business on Jan. 6, 2015.
November 18, 2014
07:59 EDTAAgilent downgraded to Market Perform at Cowen
Subscribe for More Information
07:00 EDTAAgilent downgraded to Market Perform from Outperform at Cowen
November 17, 2014
16:09 EDTAAgilent plans to return $500M in capital to shareholders in FY15
Subscribe for More Information
16:07 EDTAAgilent sees FY15 EPS $1.68-$1.78, consensus $1.74
Subscribe for More Information
16:06 EDTAAgilent sees Q1 EPS 39c-43c, consensus 42c
Subscribe for More Information
16:06 EDTAAgilent reports Q4 EPS 88c, consensus 89c
Subscribe for More Information
15:16 EDTANotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Agilent Technologies (A), consensus 89c; Jacobs Engineering (JEC), consensus 86c; Urban Outfitters (URBN), consensus 41c; Omega Protein (OME), consensus 30c.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use